Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for ...

It might take a while longer, but Pfizer is on the path to recovery. 10 stocks we like better than Pfizer › Is 2026 the year Pfizer (NYSE: PFE) finally turns things around? The company has been ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...

Pfizer Inc. (PFE) named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer enters the new year as a company in transition, but one with a heavily fortified bottom line. Management has set a revenue floor of approximately $61 billion for 2026. This is a realistic, ...